Oyster Point Pharma is a biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. Co.'s development pipeline includes: Small Molecule Programs, which consist of Tyrvaya (varenicline solution) Nasal Spray for the indication of dry eye disease, and OC-01 (varenicline solution) nasal spray for the indication of Neurotrophic Keratopathy Stage 1; and ETF Gene Therapy Approach, which consists of OC-101 adeno-associated virus (AAV)-Nerve Growth Factor for the indication of Neurotrophic Keratopathy Stage 2 and 3, and OC-103 AAV for the indication of Vernal Keratoconjunctivitis/Severe Allergic Conjunctivitis. The OYST average annual return since 2019 is shown above.
The Average Annual Return on the OYST average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OYST average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OYST average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|